Repligen reported $209M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Agilent USD 1.88B 43M Jun/2026
Align Technology USD 1.02B 40M Sep/2026
Bio Techne USD 299.71M 21.49M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Bruker USD 874M 35.5M Sep/2026
Charles River Laboratories USD 982.7M 17.3M Sep/2026
Danaher USD 6.55B 254M Sep/2026
Dentsply International USD 836M 62M Sep/2026
General Electric Aerospace USD 14.12B 1.49B Sep/2026
Henry Schein USD 3.47B 10M Sep/2026
Illumina USD 1.17B 10M Sep/2026
IQVIA Holdings USD 4.43B 60M Sep/2026
Mettler Toledo International USD 1.09B 60M Sep/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
OraSure Technologies USD 26.76M 322K Dec/2025
Pacific Biosciences Of California USD 44.64M 6.2M Dec/2025
Pfizer USD 16.6B 1.57B Sep/2026
Repligen USD 209M 5M Sep/2026
Revvity USD 729M 680K Sep/2026
Standard Biotools USD 20.1M 996K Jun/2026
Thermo Fisher Scientific USD 12.14B 147M Sep/2026
Waters USD 1.77B 130M Sep/2026
West Pharmaceutical Services USD 874.5M 2.2M Sep/2026